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ABSTRACT
Recent studies have shown that inhibition of stress-induced signaling via the mitogen
activated protein kinase (MAPK) pathway can potentiate the toxic effects of chemothera-
peutic drugs and ionizing radiation. Because of these observations, we have further inves-
tigated the impact upon growth and survival of mammary (MDA-MB-231, MCF7, T47D),
prostate (DU145, LNCaP, PC3) and squamous (A431) carcinoma cells following irradia-
tion and combined long-term exposure to MEK1/2 inhibitors. Exposure of carcinoma cells
to ionizing radiation resulted in MAPK pathway activation initially (0-4h) and modestly
enhanced MAPK activity at later times (24h-96h). Inhibition of radiation-induced MAPK
activation using MEK1/2 inhibitors potentiated radiation-induced apoptosis in two
waves, at 21-30h and 96-144h after exposure. The potentiation of apoptosis was not
observed in MCF7, LNCaP, or PC3 cells. At 24h, the potentiation of apoptosis was inde-
pendent of radiation dose whereas at 108h, apoptosis correlated with increasing dose.
Removal of the MEK1/2 inhibitor either 6h or 12h after exposure abolished the potenti-
ation of apoptosis at 24h. At this time, the potentiation of apoptosis correlated with
cleavage of pro-caspases -8, -9 and -3, and with release of cytochrome c into the cytosol.
Inhibition of caspase function using a pan-caspase inhibitor ZVAD blocked the enhanced
apoptotic response at 24h. Selective inhibition of caspase 9 with LEHD or caspase 8 with
IETD partially blunted the apopt tic response in MDA-MB-231, DU145 and A431 cells,
whereas inhibition of both caspases reduced the response by >90%. Removal of the
MEK1/2 inhibitor either 24h or 48h after exposure abolished the potentiation of 
apoptosis at 108h. Incubation of cells with ZVAD for 108h also abolished the potentiation
of apoptosis. In general agreement with the finding that prolonged inhibition of MEK1/2
was required to enhance radiation-induced apoptosis at 108h, omission of MEK1/2
inhibitor from the culture media during assessment of clonogenic survival resulted in either
little or no significant alteration in radiosensitivity. Collectively, our data show that 
combined exposure to radiation and MEK1/2 inhibitors can reduce survival in some, but
not all, tumor cell types. Prolonged blunting of MAPK pathway function following radi-
ation exposure is required for MEK1/2 inhibitors to have any effect on carcinoma cell
radiosensitivity.
INTRODUCTION
Mammary and prostate carcinomas are two of the leading causes of death for American
women and men, respectively. A variety of modalities including surgery, chemotherapy
and ionizing radiation have been used to treat these diseases with variable success at 
preventing re-occurrence. In vitro, carcinoma cells are often found to be relatively resistant
to the toxic effects of ionizing radiation and thus further investigations designed to manip-
ulate carcinoma cell survival are warranted. 
The mechanisms by which radiation can either increase cell death or alter the prolifer-
ative rate of surviving cells are not fully understood. Recently, radiation has been shown to
activate multiple signaling pathways within cells which can alter cell survival or proliferation
depending upon the radiation dose, the cell type, and the culture conditions.1-4 Several
groups have shown that the epidermal growth factor receptor (EGFR) is activated in
response to irradiation of carcinoma cells.1,5-8 Radiation exposure, via activation of 
the EGFR, can activate the Mitogen Activated Protein kinase (MAPK) pathway to a level
similar to that observed by physiologic, growth stimulatory, EGF concentrations.5,6,9-11
The ability of the “classical” mitogen activated protein kinase (MAPK) pathway to 
regulate proliferation versus differentiation and survival appears to depend upon the cell
type examined, as well as upon the amplitude and duration of MAPK activation. A short
activation of the MAPK cascade by growth factors has been correlated with increased 
proliferation, via both increased Cyclin D1 expression and an increased ability to progress
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through the G1-S transition.12 In contrast, prolonged elevation of
MAPK activity has been demonstrated to inhibit DNA synthesis, via
super-induction of the cyclin dependent kinase inhibitor proteins
p16 and p21.13 In addition to a role for MAPK signaling during
G1/S phase, it has also been argued that MAPK signaling is involved
in the ability of cells to progress through G2/M phase, particularly
in cells following drug-induced growth arrest.14,15
The proliferation of many carcinoma cells in vitro and in vivo is
in part regulated by the synthesis and autocrine actions of ligands
such as transforming growth factor α(TGFα).8,11 Irradiation of
tumor cells can increase expression of TGFα, and this has been 
proposed to increase the proliferative rate of surviving cells.16,17
Increased proliferative rates and poor prognosis of carcinomas in vivo
are also correlated with increased expression of the EGFR.18 MAPK
signaling has also been linked to increased expression of other mitogens
such as VEGF.19-21 Growth factors such as VEGF and TGFα, in
addition to a growth promoting role in vitro, may also play an
important role in the development of tumors in vivo due to their
abilities in the promotion of angiogenesis. Collectively, these findings
argue that radiation may have a self-limiting effect on its toxicity 
via increased autocrine growth factor function and the activity of
downstream signaling modules, including the MAPK pathway.
We and others have recently demonstrated that increased signaling
by the EGFR and the MAPK pathway can be cytoprotective versus
ionizing radiation and various cytotoxic drugs in diverse cancer cell
lines.1,8,10,11,22 Of note, several other groups have not observed
MAPK signaling to be protective, which in part may be explained 
by both cell line differences and the fact that the ability of MAPK
inhibition to sensitize DU145 cells in colony formation assays
required a prolonged >24h blunting of MAPK function.11,23-25
Despite the interest in MEK1/2 inhibitors as an anti-neoplastic
agents by promoting growth arrest, the mechanisms by which they
can induce cell death after irradiation remain incompletely understood.
The studies in this report were designed to determine the mecha-
nisms by which MEK1/2 inhibitors enhance radiosensitivity in
carcinoma cells.
MATERIALS AND METHODS
Agarose conjugated anti-p42MAPK antibody (sc-154-AC) was from Santa
Cruz Biotechnology (Santa Cruz Biotechnologies, CA).  Phospho-p44/42
MAP kinase (Thr202/Tyr204) antibody (1:1000, rabbit polyclonal, NEB,
Beverly, MA), anti-human Bcl-2 (1:2000, mouse monoclonal, Dako,
Carpinteria, CA), Bax (N-20, 1:2000, rabbit polyclonal, Santa Cruz
Biotechnology Inc.), Bcl-XS/L (S-18, 1:500, rabbit polyclonal, Santa Cruz
Biotechnology Inc.), anti-human/mouse XIAP (1:500, rabbit polyclonal,
R&D System, Minneapolis, MN), anti-cytochrome c (1:500, mouse mono-
clonal, Pharmingen), anti-caspase-3 (1:1000, rabbit polyclonal, Pharmingen),
cleaved-caspase-3 (17kDa) antibody (1:1000, rabbit polyclonal, Cell Signaling
Technology), anti-caspase-9 (1:1000, rabbit polyclonal, Pharmingen), anti-
caspase-8 (1:1000, rabbit polyclonal, Pharmingen), anti-PARP (1:2500,
mouse monoclonal, Calbiochem), and cleaved PARP (89kDa) antibody
(1:1000, rabbit polyclonal, Cell Signaling Technology). Radiolabelled 
[γ-32P]-ATP was from NEN. Selective MEK1/2 inhibitors (PD184352,
PD98059, and UO126) were supplied by Calbiochem (San Diego, CA) as
powder, dissolved in sterile DMSO, and stored frozen under light-protected
conditions at -20˚C. In all experiments, the final concentration of DMSO
did not exceed 0.1%. The pan-caspase inhibitor (Z-VAD-FMK), the caspase
8 inhibitor (Z-IETD-FMK), and the caspase 9 inhibitor (Z-LEHD-FMK)
were purchased from Enzyme System Products (Livermore, CA), dissolved
in DMSO and stored at 4 oC. Western immunoblotting was performed
using the Amersham Enhanced Chemi-Luminescence (E.C.L.) system.
Other reagents were as in references 8 and 26.
Culture of Carcinoma Cells. Asynchronous cells (MCF7; MDA-MB-
231; PC3; LNCaP; T47D; DU145; A431) were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 5% (v/v) fetal calf
serum at 37˚C in 95% (v/v) air/5% (v/v) CO2. Cells were plated at a 
density 3.2 x 104 cells/cm2 plate area and grown for 24-36h prior to further
experimentation.
Exposure of Cells to Ionizing Radiation and Cell Homogenization.
Cells were cultured in DMEM + 5% (v/v) fetal calf serum as above.
U0126/PD98059/PD184352 treatment was from a 100 mM stock solution
and the maximal concentration of vehicle (DMSO) in media was 0.02%
(v/v).  Cells were irradiated to a total of 2 Gy using a 60Co source at dose
rate of 2.1 Gy/min. Cells were maintained at 37˚C throughout the experiment
except during the ~1 min irradiation itself. Zero time is designated as the
time point at which exposure to radiation ceased. After radiation-treatment
cells were incubated for specified times followed by aspiration of media and
snap freezing at 70˚C on dry ice. Cells were homogenized in 1 ml ice cold
buffer A [25 mM β-glycerophosphate, pH 7.4 at 4˚C, 5 mM EDTA, 5 mM
EGTA, 5 mM benzamidine, 1 mM phenylmethyl sulphonylfluoride, 1
µg/ml soybean trypsin inhibitor, 40 µg/ml pepstatin A, 1 µM Microcystin-LR,
0.5 mM sodium orthovanadate, 0.5 mM sodium pyrophosphate, 0.05%
(w/v) sodium deoxycholate, 1% (v/v) Triton X100, 0.1% (v/v) 2-mercap-
toethanol], with trituration using a P1000 pipette to lyse the cells.
Homogenates were stored on ice prior to clarification by centrifugation
(4˚C).
Immunoprecipitations from Lysates. Fifty microliters of Protein A
agarose (Ag) slurry (25 µl bead volume) was washed twice with 1 ml PBS
containing 0.1% (v/v) Tween 20, and resuspended in 0.1 ml of the same
buffer. Antibodies (2 µg, 20 µl), serum (20 µl) were added to each tube and
incubated (3h, 4˚C). For pre-conjugated antibodies, 10 µl of slurry (4 µg
antibody) was used. Clarified equal aliquots of lysates (0.25 ml, ~100 µg
total protein) were mixed with Ag-conjugated antibodies in duplicate using
gentle agitation (2.5h, 4˚C). Ag-antibody-antigen complexes were recovered
by centrifugation, the supernatant discarded, and washed (10 min) sequen-
tially with 0.5 ml buffer A (twice), PBS and buffer B [25 mM Hepes, pH
7.4, 0.1 mM Na3VO4].
Assay of p42MAPK Activity. Immunoprecipitates were incubated (final
volume 50 µl) with 50 µl of buffer B containing 0.2 mM [g-32P]ATP (5000
cpm/pmol), 1 µM Microcystin- LR, 0.5 mg/ml myelin basic protein
(MBP), which initiated reactions at time = 0. After 20 min, 40 µl of the
reaction mixtures were spotted onto a 2 cm circle of P81 paper (Whatman,
Maidstone, England) and immediately placed into 180 mM phosphoric
acid. Papers were washed four times (10 min each) with phosphoric acid,
and once with acetone, and 32P-incorporation into MBP was quantified by
liquid scintillation spectroscopy.
SDS Poly-Acrylamide Gel Electrophoresis (SDS PAGE) and Western
Blotting. Cells were irradiated and at specified time points/treatments
media aspirated and the plates snap frozen. Cells were lysed with homoge-
nization buffer and subjected to immunoprecipitation. Immunoprecipitates
were solubilized with 100 µl 5X SDS PAGE sample buffer (10% (w/v)
SDS), diluted to 250 µl with distilled water, and placed in a 100?C dry bath
for 15 min. One hundred microliter aliquots of each time point were 
subjected to SDS PAGE on 10% (w/v) acrylamide gels. Gels were trans-
ferred to nitrocellulose by the Method of Towbin and Western blotting
using specific antibodies performed as indicated. Blots were developed using
Enhanced Chemi-Luminescence (Amersham) using Fuji RX x-ray film.
Blots were digitally scanned using Adobe Photoshop 5.5, their color
removed, and Figures created in Microsoft PowerPoint.
Terminal Uridyl-Nucleotide End Labeling (TUNEL) for Apoptosis.
Cells were treated with or without varying concentrations of
U0126/PD184352/PD98059/DMSO control 30 min prior to irradiation
and irradiated (2 Gy). Cells were isolated 24h after irradiation by trypsinization
followed by centrifugation onto glass slides (cytospin). Terminal Uridyl-
Nucleotide End Labeling (TUNEL) was performed on these cells as
described in references 8, 26, 28. Randomly selected fields of fixed cells
(~150 cells per field, n=5 per slide) were counted initially using propidium
iodide counter stain, followed by examination and counting of TUNEL
positive staining cells of the same field under FITC/fluorescence light.
Analysis of Cytosolic Cytochrome C. At various times after irradiation/
MEK1/2 inhibitor treatment, 2 x 106 cells were washed in PBS and lysed by
incubating for 30 seconds in lysis buffer (75mM NaCl, 8mM Na2HPO4,
1mM NaH2PO4, 1mM EDTA, and 350 µg/ml digitonin). The lysates were
centrifuged at 12,000g for 1 min, and supernatant was collected and added
to equal volume of 2X sample buffer. The protein samples were quantified,
separated by 15% SDS-PAGE, and subjected to immunoblot analysis as
described above. Anti-cytochrome c (mouse monoclonal, Pharmingen) was
used as primary antibody at a dilution of 1: 500.
Analysis of Mitochondrial Membrane Potential (mm). At various times
after irradiation/MEK1/2 inhibitor treatment, 2 x 105 cells were incubated
in situ with 40nM 3,3-dihexyloxacarbocynine (DiOC6, Molecular Probes
Inc. Eugene, OR) in PBS at 37oC for 20 min, isolated by trypsinization, and
then analyzed by flow cytometry as described in references 26 and 28. The
percentage of cells exhibiting low level of DiOC6 up-take, which reflects
loss of mitochondrial membrane potential, was determined using a Becton-
Dickinson FACScan analyzer. 
Colony Forming (Clonogenic) Assay. Cells were pre-treated with
MEK1/2 inhibitor as indicated, 2h prior to exposure. Cells were irradiated
(2 Gy). After 48h, cells were isolated by tryptic digestion and re-plated as
single cell suspensions plated on Linbro® plates at densities of 500 cells/well
and 1000 cells/well. Colony formation was defined as a colony of 50 cells
or greater, 10-14 days after plating.
Data Analysis. Comparison of the effects of treatments was done using
one way analysis of variance and a two tailed t-test. Differences with a 
p-value of <0.05 were considered statistically significant. Experiments
shown, except where indicated, are the means of multiple individual points
from multiple separate experiments (±SEM). Statistical analyses were made
using SigmaPlot and SigmaStat.
RESULTS
Radiation Induces Activation of the MAPK Pathway in Carcinoma
Cells. The ability of ionizing radiation to modulate MAPK activity was
investigated in carcinoma cells (Fig. 1 and Fig. 2). In the representative 
studies shown, radiation caused immediate primary activation of the MAPK
pathway (0-10 min) followed by a later secondary activation (Fig. 1A).
Incubation of cells with a relatively specific inhibitor of MEK1/2/5
(PD98059), blunted the ability of radiation to activate MAPK (Fig. 1A).  In
some cell types, e.g., LNCaP, radiation appeared to cause a reduction in
MAPK activity (data not shown). Of note, basal MAPK activity varied
greatly between the cell lines used in our study (Fig. 1B). Subsequent 
studies examined radiation-induced MAPK activity 24h-120h after exposure
(Fig. 2). Radiation enhanced MAPK activity ~1.3 to 1.4-fold above basal
levels 24h following exposure, which declined to control levels by 72h and
remained at or near control levels until 120h after exposure. In contrast,
radiation appeared to reduce MAPK activity in cells treated with a MEK1/2
inhibitor beyond that of MEK1/2 inhibitor alone, 48-120h after exposure
(Fig. 2A and Fig. 2B).
Inhibition of Radiation-Induced MAPK Signaling Enhances
Radiation-Induced Apoptosis at 24h. The impact of MEK1/2 inhibitors on
radiation-induced apoptosis was initially determined 24h after
treatment/exposure (Figs. 3A-3G). Inhibition of radiation-induced MAPK
signaling had a variable effect on the levels of apoptosis observed 24h after
exposure: for example, MCF7 and PC3 cells exhibited no potentiation in
apoptotic cell killing whereas A431 cells showed a greater sensitivity to
MEK1/2 inhibitors alone as well as a larger significant enhancement in double
stranded DNA breaks by radiation. In the majority of cell lines examined,
with the exception of T47D, the basal activity of ERK1/2 correlated with
the ability of MEK1/2 inhibitors to enhance apoptosis (compare Fig. 1B to
Fig. 3). Similar data were evident when plasma membrane integrity and
staining of DNA was assessed using 7AAD (Figs. 4A-4D). Removal of the
MEK1/2 inhibitor either 6h or 12h after irradiation abolished the potentiation
of apoptosis at 24h (Fig. 5A), and increasing the radiation dose did not enhance
the potentiation of apoptosis by MEK1/2 inhibitors at this time (Fig. 5B). 
Simplistically, apoptosis is mediated via two inter-related cascades of
proteases (caspases); the intrinsic mitochondrial (caspase 9) pathway and the
extrinsic death receptor (caspase 8) pathway. Caspase 3 can also mediate
additional activation of caspase 9 via a feed-forward amplification loop
involving it in caspase 8 processing, leading to BID cleavage and further
cytochrome c release from the mitochondrion. We found that the potentia-
tion of radiation-induced apoptosis at 24h was blocked by the pan-caspase
inhibitor ZVAD and in MDA-MB-231, DU145 and A431 cells partially
blunted by individual additions of either the caspase 8 inhibitor IETD or
the caspase 9 inhibitor LEHD (Figs. 6A-6E). Combined use of both IETD
and LEHD was required to completely prevent the apoptotic response in
these cells. In contrast, IETD completely blocked the apoptotic response in
T47D cells. In agreement with data arguing that both caspase 8 and caspase 9
played roles in the apoptotic process, enhanced apoptosis (Fig. 4 and Fig. 6)
correlated with cleavage and reduced expression of pro-caspase 8, pro-caspase 9
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Figure 1. Ionizing radiation activates the MAPK pathway in carcinoma cells,
which is blocked by inhibitors of MEK1/2. Cells were cultured as described
in Methods. A. A431 and DU145 cells. B. Basal MAPK activity in MDA-MB-231,
A431, DU145, MCF7, T47D, PC3 and LNCaP cells. Cells were pre-treated 
for 30 min with MEK1/2 inhibitor (PD98059; A431; 10 µM; DU145 25
µM) followed by irradiation (2 Gy) and MAPK activity determined over 
0-1440 min as in Methods. Cells were lysed and portions (~100 µg) from
each plate used to immunoprecipitate MAPK followed by immune-complex
kinase assays as in Methods. In Panel A, MAPK activity data are duplicate
values from a single representative experiment and are shown as -fold
increases in 32P-incorporation into MBP substrate. In Panel B, data are shown
as specific MAPK activity (fmol/min/mg) ± SEM (n=3).
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and pro-caspase 3 in A431 and DU145 cells (Fig. 7A and Fig. 7B). Of note,
in A431 cells, significant amounts of “active” p36 caspase 9 were observed
in control cells. Combined exposure to radiation and MEK1/2 inhibitors
also promoted release of cytochrome c from the mitochondria into the cyto-
plasm but surprisingly at this time did not alter the mitochondrial membrane
potential (Fig. 7C). Loss of the mitochondrial membrane potential was variably
observed within the following 6-12h (data not shown). 
Because removal of the MEK1/2 inhibitor at 12h abolished the potentiation
of apoptosis at 24h (Fig. 5), further studies were performed to examine the
time course of pro-caspase cleavage. Reduced expression of p32 pro-caspase
3 and increased expression of p17 active caspase 3 was not observed 12h 
following combined radiation and MEK1/2 inhibitor exposure (Fig. 7D),
indicating that at this time cells were not undergoing apoptosis (in agree-
ment with Fig. 5A). However, at 18h, 21h and 24h after exposure loss of
p32, and increased p17, expression was observed. The increase in p17
expression was greater in cells exposed to radiation and MEK1/2 inhibitor
than to either radiation or MEK1/2 inhibitor alone. These findings suggest
that MEK1/2 activity must be depressed for at least 18h to obtain a poten-
tiation of radiation-induced apoptosis at 24h. 
Inhibition of MAPK Signaling Enhances Radiation-Induced Apoptosis
96-144h After Exposure, Which is Dependent Upon Prolonged Inhibition
of the MAPK Pathway. In a previous study, we had argued that inhibition
of the MAPK pathway enhanced radiation-induced apoptosis in two waves,
one at ~24h and a second ~96h after exposure. To further investigate these
observations, we examined both the percentage apoptosis and the expression
and integrity of pro-caspases in A413 and DU145 cells 24h-120h after 
irradiation (Fig. 8 and Fig. 9). Sixty hours after exposure, apoptosis had
returned to near basal levels under all conditions (data not shown).
Figure 2. MAPK pathway activity in carcinoma cells 24-120h after exposure
to ionizing radiation. Cells were cultured as described in Methods. A. A431
cells. B. DU145 cells. Cells were pre-treated for 30 min with MEK1/2
inhibitor (PD98059, 10 µM A431; 25 µM DU145) followed by irradiation
(2 Gy) and MAPK activity determined over 24h-120h as in Methods. Cells
were lysed and portions (~100 µg) from each plate used to immunopre-
cipitate MAPK followed by immune-complex kinase assays as in Methods.
MAPK activity data are duplicate values from a single representative exper-
iment (n=3) and are shown as -fold increases in 32P-incorporation into MBP
substrate.
Figure 3. Combined exposure of carcinoma cells to ionizing radiation and
MEK1/2 inhibitors causes apoptosis. Cells were incubated with matched
vehicle control (DMSO) or with either 10 µM PD98059 (A431) or 25 µM
PD98059 (MDA-MB-231, MCF7, T47D, DU145, LNCaP) alone. Cells were
either exposed to radiation (2 Gy) or mock irradiated.  Portions of cells were
taken 24 hours post irradiation and fixed onto slides by cytocentrifuge 
followed by staining for double stranded DNA breaks as in Methods. A.
MDA-MB-231 cells. B. MCF7 cells. C. DU145 cells. D. T47D cells. E. A431
cells. F. LNCaP cells. G. PC3 cells.  Data shown are the mean number of
staining cells from randomly selected fields of fixed cells (n=5 per slide, ±
SEM), which were examined and counted via fluorescent light microscopy.
*p <0.05 greater than corresponding value in unirradiated cells.
However, 108h after irradiation, the percentage of cells undergoing apoptosis
in MEK1/2 inhibited and irradiated cells had again increased (Fig. 8A). The
potentiation of apoptosis at 108h appeared to correlate with increasing 
radiation dose (Fig. 8B). Of note, removal of MEK1/2 inhibitor at either
24h or 48h after exposure abolished the increase in apoptosis at 108h (Fig.
8A, data not shown). Removal at 72h, however, still permitted a limited
apoptotic response from these cells (data not shown). These findings corre-
lated with modulation of cellular radiosensitivity by MEK1/2 inhibitors in
clonogenic survival assays (Table 1): in some cell types e.g., DU145 and
A431, removal of the inhibitor 48h after exposure during re-plating abolished
any impact of MEK1/2 inhibitors on clonogenic radiosensitivity. In contrast,
other cell types e.g. MDA-MB-231 appeared to be radiosensitized even
when the inhibitor was removed after 48h. In agreement with the finding
that apoptosis had again increased at later times, prolonged inhibition of
MEK1/2 enhanced the radiation-induced cleavage of pro-caspases 96-144h
after exposure (Fig. 9A and Fig. 9B). 
Because apoptosis and caspase cleavage were observed at later times, we
investigated whether the pan-caspase inhibitor ZVAD could block this
process and whether enhanced apoptosis played an important role in the 
previously reported enhancement in radiosensitivity caused by MAPK inhi-
bition. Small molecule inhibitors of caspases are relatively unstable, and in
all of the following experiments ZVAD was re-supplemented into the media
every 24h. Prolonged exposure to ZVAD blocked the potentiation of apoptosis
at later times (Fig. 10) and also the cleavage of caspase 3 (data not shown).
Collectively, these data argue that enhanced radiosensitivity caused by
MEK1/2 inhibition is, in part, due to increased late phase apoptosis.
DISCUSSION
Previous investigations by this group have demonstrated that low
dose radiation exposure of carcinoma cells, in combination with
inhibition of MEK1/2, causes a small but statistically significant
increase in radiation-induced apoptosis within 24h. Prolonged inhi-
bition of MEK1/2 caused a second wave of apoptosis 4-6 days after
exposure in DU145 cells. Removal of the MEK1/2 inhibitor at 24h
was found to abolish the second apoptosis wave and any impact
upon long-term clonogenic survival. The studies described in this
manuscript were designed to determine the mechanisms by which
MEK1/2 inhibitors enhance apoptosis at both 24h and in the 
second wave at 108h.
We initially compared a variety of carcinoma cell types in their
abilities to be killed by radiation in the presence or absence of 
a MEK1/2 inhibitor. Low dose radiation as a single agent was 
relatively ineffective at enhancing apoptosis in all of the cell types
examined, including MCF7 and LNCaP that express wild type p53.
In all cell types that had elevated basal MAPK activity greater than
10 fmol/min/mg (A431, MDA-MB-231, DU145), MEK1/2
inhibitors weakly potentiated radiation-induced apoptosis to 
varying degrees. In cell types that had basal MAPK activity less than
10 fmol/min/mg (MCF7, PC3, LNCaP, T47D), with the exception
of T47D, no potentiation of DNA strand breakage was observed
using MEK1/2 inhibitors. Of note, serum starved/growt arrested
cells also did not exhibit a potentiation of apoptosis (unpublished
data). Within this group, it is also of note that LNCaP and PC3 cells
do not express the inositol phospholipid phosphatase PTEN.27 Loss
of PTEN suggests these cells may utilize the PI 3-kinase signaling
pathway, rather than the MAPK pathway, as a key growth and 
survival control signaling module. Collectively, these findings 
suggest that cells, which have elevated basal MAPK activity, are more
responsive to MEK1/2 inhibitors as radiosensitizers than those with
low basal MAPK activity.
Previously, we had discovered that removal of MEK1/2 inhibitor
6h following irradiation abolished the potentiation of apoptosis 24h
afterwards. In the present study, we discovered that removal of the
MEK1/2 inhibitor 12h-18h after exposure also abolished the poten-
tiation of killing at 24h. Removal of the inhibitor at 18h had a 
partial blunting effect on the apoptotic response. These findings 
correlated with the cleavage of p32 pro-caspase 3: processing of pro-
caspase 3 to p17 active caspase 3 was not observed until 18-21h after
exposure. These findings suggest that prolonged blunting of MAPK
signaling is required to enhance radiation-induced cell killing at
24h. The precise mechanisms that promote cell killing remain to be
determined.
Two upstream pathways, the intrinsic and the extrinsic, mediate
cleavage and activation of the effector pro-caspase 3. The intrinsic
pathway utilizes the mitochondrion, cytochrome c and pro-caspase
9 and the extrinsic pathway that utilizes death receptors and pro-
caspase 8. We found that combined exposure to radiation and
MEK1/2 inhibitors caused release of cytochrome c from the mito-
chondria into the cytosol within 24h, but did not promote a large
reduction in the mitochondrial membrane potential. 
Induction of apoptosis, notably by chemotherapeutic drugs, has
been linked to mitochondrial damage, including loss of the mito-
chondrial membrane potential or release of pro-apoptotic proteins
from the mitochondria, such as cytochrome c. There is controversy
regarding which of these events represents the central executioner of
apoptosis, and the induction of apoptosis in both the presence or the
absence of cytochrome c release has been described.29 Release of
cytochrome c is also often found to precede loss of the mitochondr-
ial membrane potential, ψm.
30 The present findings suggest that
cytochrome c release represents an important primary event in cells
induced to undergo apoptosis when they are treated with MEK1/2
inhibitors and exposed to radiation. 
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Figure 4. Combined exposure of
carcinoma cells to ionizing radiation
and MEK1/2 inhibitors increases
cell death as judged by 7AAD
staining. Cells were incubated with
matched vehicle control (DMSO) or
with either 10µM PD98059
(A431) or 25 µM PD98059
(MDA-MB-231, T47D, DU145)
alone. Cells were either exposed to
radiation (2 Gy) or mock irradiated.
Portions of cells were taken 24
hours post irradiation and incubated
with 7AAD (10 µg/ml final) for
30 min at 37˚C as in Methods. Cells
were subjected to flow cytometric
analysis to determine the percent-
age of cells incorporating 7AAD. A.
MDA-MB-231 cells. B. DU145 cells.
C. A431 cells. D. T47D cells. Data
shown are the mean percentage of
staining cells (3 parallel individual
experiments ± SEM). *p <0.05
greater than corresponding value in
unirradiated cells.
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Figure 5. Combined exposure of A431 and DU145 carcinoma cells to ionizing radiation and MEK1/2 inhibitors causes apoptosis which requires >12h of
incubation with MEK1/2 inhibitor.  Cells were incubated with matched vehicle control (DMSO) or with either 10 µM PD98059 (A431) or 25 µM PD98059
(DU145) alone. Cells were either exposed to radiation (2 Gy, 7.5 Gy) or mock irradiated.  Cells were either washed 6h, 12h, 18h and 21h following
exposure with media containing either vehicle or PD98059. All cells were taken 24 hours post irradiation and fixed onto slides by cytocentrifuge followed
by staining for double stranded DNA breaks as in Methods. A. Cells with MEK1/2 inhibitor removed at 6h, 12h, 18h, and 21h after exposure. B. Cells
without MEK1/2 inhibitor removal irradiated with either 2 Gy or 7.5 Gy. Percentage apoptosis determined at 24h. Data shown are the mean number of
staining cells from randomly selected fields of fixed cells (n=5 per slide, 3 parallel individual experiments ± SEM) which were examined and counted via
fluorescent light microscopy. *p <0.05 greater than irradiated value.
Figure 6. The potentiation of apoptosis by combined irradiation and MEK1/2 inhibition requires both caspase 9 and caspase 8 functions. Cells were either
treated with either vehicle, with IETD (20 µM), with LEHD (20 µM) or with both IETD and LEHD. In parallel, cells were incubated with matched vehicle con-
trol (DMSO) or with PD98059. Cells were either exposed to radiation (2 Gy) or mock irradiated. Portions of cells were taken 24 hours post irradiation and
fixed onto slides by cytocentrifuge followed by staining for double stranded DNA breaks as in Methods. A. MDA-MB-231 cells. B. MCF7 cells. C. T47D
cells. D. DU145 cells. E. A431 cells.  Data shown are the mean number of staining cells from randomly selected fields of fixed cells (n=5 per slide, ± SEM)
which were examined and counted via fluorescent light microscopy. #p <0.05 greater than corresponding value in unirradiated cells; *p <0.05 greater
than control value;%p <0.05 less than corresponding value in cells not treated with caspase inhibitor. Cells treated with the pan-caspase inhibitor ZVAD (20
µM) exhibited little or no apoptosis (data not shown).
The apoptotic responses of the various cell lines examined, 
surprisingly, differed with respect to inhibition of caspase 8 and 
caspase 9. In MDA-MB-231, A431 and DU145 cells, inhibitors of
caspase 8 and caspase 9 individually had partial effects at blunting
the apoptotic response. In MCF7 cells, that had little apoptotic
response, either inhibitor abolished increases in cell death. In 
contrast, caspase 9 inhibitors had little impact on the apoptotic
response of T47D mammary carcinoma cells whereas inhibitors of
caspase 8 completely blocked apoptosis in these cells. These findings
suggest that the mechanism by which MEK1/2 inhibitors potentiate
cell killing, 24h after exposure, is cell-type specific. Caspase 9
inhibitors had no effect on the apoptotic response in T47D cells 
suggesting that MEK1/2 inhibitors are promoting death receptor
signaling, as has previously been demonstrated by this group in 
primary hepatocytes treated with bile acids.28
Previously, we have presented evidence that inhibition of
MEK1/2 can radiosensitize cells when they are exposed repeatedly to
low dose ionizing radiation. In these studies, cells were irradiated
three times with 2 Gy per exposure and incubated with MEK1/2
inhibitors for 96 hours prior to re-plating.8 In the present study we
exposed cells to a single 2 Gy dose of radiation in the presence or
absence of MEK1/2 inhibitor for 48h and examined apoptosis and
clonogenic survival over the following week to fourteen days.
Radiation, even several days after exposure, caused relatively little
apoptosis in A431 and DU145 cells. However, the presence of
MEK1/2 inhibitor, while by itself only marginally toxic, caused a
significant enhancement in radiation-induced apoptosis. The 
pan-caspase inhibitor ZVAD blocked the increase in apoptosis.
When the MEK1/2 inhibitor was removed 24h and 48h after 
irradiation, no enhancement in late phase apoptosis occurred, which
correlated with negative data obtained when clonogenic survival was
measured in the absence of this inhibitor. In contrast, when the
MEK1/2 inhibitor was removed at 72h, a partial blunting effect on
the potentiation of apoptosis at 108h became evident. Thus incuba-
tion of cells in the presence of a MEK1/2 inhibitor for ~72h, but not
48h, appears competent to produce a commitment for enhanced
radiation-induced apoptosis at time periods distant to the initial
exposure. These findings suggest that prolonged blunting of MAPK
signaling is required to enhance radiation-induced cell killing at
108h. The precise mechanisms by which cell killing is promoted at
this time point remain to be determined. 
Surprisingly, in MDA-MB-231 and MCF7 cells, however, the
MEK1/2 inhibitor PD98059 caused radio-sensitization in clono-
genic survival assays, even though the drug was removed 48h after
irradiation. The apoptotic responses of MCF7 cells at the 24h-48h
time points were negligible, implying that in addition to potentiating
radiation-induced apoptosis, MEK1/2 inhibition can also promote
radiation-induced cell killing by other non-apoptotic mechanisms.
Further studies will be required to determine: the mechanisms by
which MEK1/2 inhibitors commit cells  and then trigger an apop-
totic response 18-24h after exposure, and the mechanisms by which
MEK1/2 inhibitors commit cells and then trigger an apoptotic
response 48-72h after irradiation.     
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Figure 7. Combined treatment of A431 and DU145 cells with ionizing 
radiation and MEK1/2 inhibitors enhances the cleavage of pro-caspase 3.
Cells were incubated with matched vehicle control (DMSO) or with
PD98059. Cells were either exposed to radiation (2 Gy) or mock irradiat-
ed.  Portions of cells were taken 24 hours post irradiation and lysed in SDS
PAGE buffer containing bromophenol blue as described in Methods. Cells
were subjected to SDS PAGE followed by immunoblotting to determine: A.
In A431 cells at 24h, the expression/integrity of pro-caspases -3, -8 and -
9. B. In DU145 cells at 24h, the expression/integrity of pro-caspases -3, -8
and -9. C. Mitochondrial membrane potential in A431 and DU145 cells
24h after exposure: inset panel, cytosolic cytochrome c levels 24h after
exposure. D. A431 cells were irradiated and treated with 10 µM
PD98059, and the integrity of pro-caspase 3 determined after 12h, 18h,
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Figure 10. The potentiation of apoptosis 96-144h after exposure by combined
irradiation and MEK1/2 inhibition is inhibited by the pan-caspase inhibitor
ZVAD. Cells were either treated with either vehicle or with ZVAD (20 µM).
In parallel, cells were incubated with matched vehicle control (DMSO) 
or with PD98059. Cells were either exposed to radiation (2 Gy) or mock
irradiated. Vehicle or ZVAD was replenished in the media every 24h.
Portions of cells were taken 108 hours post irradiation and fixed onto slides
by cytocentrifuge followed by staining for double stranded DNA breaks 
as in Methods. A. A431 cells. B. DU145 cells. Data shown are the mean
number of staining cells from randomly selected fields of fixed cells (n=5 per
slide, ± SEM) which were examined and counted via fluorescent light
microscopy. # p <0.05 greater than corresponding value in unirradiated
cells; * p <0.05 greater than control value;% p <0.05 less than corresponding
value in cells not treated with caspase inhibitor.
